Resources
15 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/12/2021 (updated 4/5/2024)
The National Center on Substance Abuse and Child Welfare (NCSACW), a program of the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Administration on Children, Youth and Families (ACYF), prepared this document to support policy makers, administrators, and service providers. The goal of the document is to foster collaborative responses across multiple systems to improve safety, permanency, and well-being outcomes for infants, recovery for their parents, and to meet the needs of families and caregivers.
Posted 3/10/2021 (updated 4/5/2024)
The 2020 National Drug Threat Assessment (NDTA) is a comprehensive assessment of the threat posed to the United States by the trafficking and abuse of illicit drugs, the diversion and abuse of licit drugs, and the laundering of proceeds generated through illicit drug sales. It also addresses the role domestic groups, including organized violent gangs, serve in domestic drug trafficking. The most widely trafficked drugs are discussed in terms of their availability, consumption and overdose related deaths, production and cultivation, transportation, and distribution.
Posted 3/2/2021 (updated 4/5/2024)
Posted 10/14/2021 (updated 4/3/2024)
Presenters reviewed resources available to rural grantees through their respective agencies.
Posted 12/15/2020 (updated 4/3/2024)
A Guide to Federal and Regional Resources.
Posted 12/15/2020 (updated 4/3/2024)
The presenter reviewed resources available to rural grantees through Substance Abuse and Mental Health Services Administration’s (SAMHSA’s) Addiction Technology Transfer Centers (ATTC) as well as other SAMHSA programs.
Posted 8/11/2020 (updated 4/2/2024)
Non-fatal opioid overdose (NFOO) is a significant cause of opioid-related morbidity in the United States. As the number of NFOOs continues to grow, it is important to understand the short- and long-term consequences of NFOO. This report examines the existing literature on the acute and chronic health and functional outcomes of individuals who experience NFOO, and also identifies differences in outcomes for NFOOs involving illicitly-manufactured fentanyl.
Posted 7/16/2020 (updated 3/28/2024)
The National Health Service Corps (NHSC) New Site Application webinar took place on Thursday, July 2, 2020, at 2:00 PM ET.
Posted 11/9/2023 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) published Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants in 2018. The National Center on Substance Abuse and Child Welfare (NCSACW) developed companion materials that offer information and strategies to support pregnant and parenting people with substance use disorders (SUDs) in the child welfare system.
Posted 10/27/2023 (updated 3/28/2024)
As announced by the Substance Abuse and Mental Health Services Administration in January 2023, clinicians no longer need a federal waiver to prescribe buprenorphine for treatment of opioid use disorder. Clinicians will still be required to register with the federal Drug Enforcement Agency (DEA) to prescribe controlled medications. On June 27, the DEA began to require that registration applicants – both new and renewing – affirm they have completed a new, one-time, eight-hour training.